Wang, M., Hoffmann, M. S., Wróbel, T., Trneny, M., Belada, D., Demirken, F., Panayiotidis, P., Jurczak, W., Zinzani, P. L., Keating, M., Yoon, S., Egyed, M., Tam, C. S., Johnson, N. A., Glusman, E. S., Lin, J., Dean, J. P., Neuenburg, J. K., Keudell, G. V. (2026). First-line ibrutinib plus venetoclax for non-blastoid mantle cell lymphoma in patients ≥65 years or with TP53 mutations. Blood. https://doi.org/10.1182/blood.2025032833